RNA that lasts longer and lands exactly where it should
RNA therapies are moving past burst-and-fade limits. New advances in circular RNA and targeted delivery could transform how we treat autoimmune disease, infections and beyond.
List view / Grid view
RNA therapies are moving past burst-and-fade limits. New advances in circular RNA and targeted delivery could transform how we treat autoimmune disease, infections and beyond.
Researchers at The University of Osaka have developed a new system to study human norovirus, with the hope of being able to develop vaccines and antiviral treatments faster.
Scientists have developed an organ-on-a-chip platform that replicates age-related immune decline, offering a long-missing tool for testing cancer vaccines in older adults.
Drug-resistant infections are on the rise, endangering global health. Neil Murray from ReNewVax explains how the company’s universal pneumococcal vaccine, RVX-001, could reduce antibiotic use and help curb antimicrobial resistance.
Japanese researchers have developed a nasal HPV vaccine that could offer a non-invasive, fertility-preserving alternative to surgery for cervical cancer.
Advances in formulation science and device technology are transforming nasal drug delivery, enhancing absorption, stability and patient adherence. This article examines the innovations driving its growth and highlights future applications ranging from systemic treatments to nose-to-brain therapies and vaccines.
CRISPR therapies depend on delivery and lipid nanoparticles are emerging as a more flexible and scalable option than viral vectors.
A new review has highlighted how three-dimensional organoid models are transforming cancer research by replicating the complexity of human tumours – bringing precision oncology closer to the clinic.
Severe flu in pregnancy may weaken the placenta and foetal brain, allowing harmful molecules to leak in and disrupt development, a new study finds
Researchers at Mount Sinai have identified three antibodies that target mpox and prevent severe disease in vivo. The work positions A35-specific antibodies as candidates for therapeutic development.
Brazilian researchers have developed a new Zika virus vaccine that is safe and effective in mice – protecting against both brain inflammation and testicular damage while avoiding cross-reactions with dengue.
The 2025 chikungunya outbreak has surged from the Indian Ocean to Europe, prompting an urgent global research response. With no antivirals and limited vaccine access, laboratories and biotech firms are under pressure to deliver solutions fast.
University of Chicago researchers have developed a scalable nanoparticle platform that self-assembles with just a temperature change – enabling safe, solvent-free delivery of proteins and RNA for vaccines and therapies.
Australian scientists have, for the first time, visualised a malaria parasite protein complex – a discovery that has led to a new mRNA vaccine capable of blocking the parasite’s reproduction in mosquitoes and potentially halting transmission.
Japanese researchers have engineered a new lipid nanoparticle that delivers mRNA to cells five times more effectively, resulting in stronger immune responses and tumour suppression in mice.